JNJ - Sarepta Therapeutics set to join S&P MidCap 400
2024-05-30 02:45:27 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
- Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
- Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts
- RBC Capital cuts Sarepta to sector perform ahead of FDA decision
- Sarepta upgraded at Oppenheimer on potential Elevidys label expansion